October 01, 2016 10:09 AM ET


Company Overview of Aimmune Therapeutics, Inc.

Executive Profile

Stephen George Dilly M.B.B.S, Ph.D.

Chief Executive Officer, President and Director, Aimmune Therapeutics, Inc.
AgeTotal Calculated CompensationThis person is connected to 4 Board Members in 4 different organizations across 5 different industries.

See Board Relationships
As of Fiscal Year 2015


Dr. Stephen George Dilly, M.B.B.S, Ph.D., has been the Chief Executive Officer of Aimmune Therapeutics, Inc. since April 2014 and serves as its President. Dr. Dilly serves as Strategic Advisor at Physic Ventures, LLC. He served as the Chief Executive officer of PhotoThera, Inc. from January 2012 to December 2012 and served as its President. He served as Chief Executive Officer and President at APT Pharmaceutical LLC from April 2006 to December 2011. He has extensive ...

Corporate Headquarters

8000 Marina Boulevard
Brisbane, California 94005

United States

Phone: 650-614-5220
Fax: 650-616-0075

Board Members Memberships

Director, Chairman of Clinical Review Committee and Member of Nominating & Corporate Governance Committee
Chief Executive Officer, President and Director


PhD 1988
University Of London
Bachelor's Degree 1982
University Of London

Other Affiliations

Annual Compensation

Total Annual Compensation$372,917

Stocks Options

Exercisable Options$595,942
Exercisable Options Value$9,195,385
Total Value of Options$9,195,385
Total Number of Options$595,942

Total Compensation

Total Annual Cash Compensation$564,917
Total Short Term Compensation$372,917
Total Calculated Compensation$3,069,512

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup


Pierre-Henri Benhamou M.D.Co-Founder, Chairman and Chief Executive Officer
DBV Technologies S.A.
Compensation as of Fiscal Year 2015.

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Aimmune Therapeutics, Inc., please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.